Cargando…

2727. Numbers Needed to Vaccinate for Prevention of Adult Pneumonia with Pneumococcal Conjugate Vaccine: Which Values Should Determine Policy?

BACKGROUND: At the meeting of the Advisory Committee on Immunization Practices (ACIP) on February 28, 2019, the US Centers for Disease Control and Prevention (CDC) and the Pneumococcal Work Group (PWG) presented data to inform the public health question of whether the 13-valent pneumococcal conjugat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gessner, Bradford D, Isturiz, Raul E, Snow, Vincenza, Jodar, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809619/ http://dx.doi.org/10.1093/ofid/ofz360.2404

Ejemplares similares

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
por: McLaughlin, John M., et al.
Publicado: (2019)

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults
por: Isturiz, Raul, et al.
Publicado: (2015)

Pneumococcal vaccination of older adults: Conjugate or polysaccharide?
por: Hollingsworth, Rosalind, et al.
Publicado: (2014)

Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine
por: Hsiao, Amber, et al.
Publicado: (2022)

1442. Pneumonia Hospitalizations Averted With 13-Valent Pneumococcal Conjugate Vaccination of Adults Aged 18–64 Years With Diabetes in the United States
por: Suaya, Jose, et al.
Publicado: (2018)

Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
por: Sings, Heather L., et al.
Publicado: (2021)

1446. Correlation Between Adult Invasive and Noninvasive Streptococcus pneumoniae Disease in 13-Valent Pneumococcal Conjugate Vaccine Serotypes in the United States
por: Suaya, Jose A, et al.
Publicado: (2018)

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design
por: McLaughlin, John M, et al.
Publicado: (2018)

Disparities in Uptake of 13-valent Pneumococcal Conjugate Vaccine among Older Adults Following Routine Recommendation in the United States
por: McLaughlin, John, et al.
Publicado: (2017)

2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults
por: Lewis, Ned, et al.
Publicado: (2019)

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies
por: Sings, Heather L, et al.
Publicado: (2019)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
por: Theilacker, Christian, et al.
Publicado: (2022)

Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”
por: Farkouh, Raymond A., et al.
Publicado: (2015)

Burden of Pneumococcal Disease in Northern Togo before the Introduction of Pneumococcal Conjugate Vaccine
por: Moïsi, Jennifer C., et al.
Publicado: (2017)

1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
por: Vojicic, Jelena, et al.
Publicado: (2018)

Impact of Pneumococcal Conjugate Vaccine on Vaccine Serotype–Specific Pneumonia
por: Klugman, Keith P, et al.
Publicado: (2020)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
por: Sabharwal, Charu, et al.
Publicado: (2022)

Prevention of Coronavirus Disease 2019 Among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions Between Streptococcus pneumoniae and Severe Acute Respiratory Syndrome Coronavirus 2 in the Respiratory Tract
por: Lewnard, Joseph A, et al.
Publicado: (2021)

Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study
por: Lewnard, Joseph A, et al.
Publicado: (2022)

1149. Contribution of S.pneumoniae Serotypes in Adults with Invasive Pneumococcal Disease (IPD) and Pneumococcal Community-acquired Pneumonia (pCAP)
por: Apodaca, Kevin, et al.
Publicado: (2023)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
por: Chilson, Erica, et al.
Publicado: (2020)

Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection
por: Dunne, Eileen M., et al.
Publicado: (2023)

Correction: Theilacker et al. PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Microorganisms 2022, 10, 127
por: Theilacker, Christian, et al.
Publicado: (2022)

Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination
por: Grant, Lindsay R, et al.
Publicado: (2022)

Dosing Schedules for Pneumococcal Conjugate Vaccine: Considerations for Policy Makers
por: Whitney, Cynthia G., et al.
Publicado: (2014)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Changes in the Pneumococcal Vaccine Serotypes in Adult Noninvasive Pneumonia after the Introduction of Pneumococcal Conjugate Vaccination for Children
por: Takeda, Hiroaki, et al.
Publicado: (2019)

Differences in Homing Potentials of Streptococcus pneumoniae–Specific Plasmablasts in Pneumococcal Pneumonia and After Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccinations
por: Palkola, Nina V., et al.
Publicado: (2015)

Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
por: Elemraid, Mohamed A., et al.
Publicado: (2013)

Serotypes in Adult Pneumococcal Pneumonia in Spain in the Era of Conjugate Vaccines
por: Fernández-Delgado, Lucía, et al.
Publicado: (2021)

2717. The Impact of Pneumococcal Conjugate Vaccine in Nonbacteremic Pneumococcal Pneumonia Among Cancer Patients
por: Lee, Yeon Joo, et al.
Publicado: (2019)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
por: Méroc, Estelle, et al.
Publicado: (2023)

2728. Proportion of Invasive Pneumococcal Disease Potentially Covered by Current and Next-Generation of Higher-Valency Pneumococcal Conjugate Vaccines in Canada, 2010–2016
por: Dion, Stephane B, et al.
Publicado: (2019)

Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance
por: Scelfo, Chiara, et al.
Publicado: (2021)

Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations
por: Naucler, Pontus, et al.
Publicado: (2017)

Impact of the 7-valent pneumococcal conjugate vaccine on the incidence of childhood pneumonia
por: ELEMRAID, M. A., et al.
Publicado: (2013)

Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine
por: Esposito, Susanna, et al.
Publicado: (2016)

Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines
por: Wyllie, Anne L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sr7sdovq7hm10cebvebrh86f82